Title:
Bioreactance is a reliable method for estimating cardiac output at rest and during exercise

Running head:
Reliability of bioreactance during graded exercise

Author names and affiliations:
Thomas W. Jones PhD\textsuperscript{a}, David Houghton PhD\textsuperscript{b}, Sophie Cassidy MRes\textsuperscript{b}, Guy A. MacGowan MD\textsuperscript{c,d}, Michael I. Trenell PhD\textsuperscript{b,c} & Djordje G. Jakovljevic PhD\textsuperscript{b,e}
\textsuperscript{a}Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
\textsuperscript{b}Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK
\textsuperscript{c}Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK
\textsuperscript{d}Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
\textsuperscript{e}RCUK Centre for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

Corresponding Author:
Djordje G. Jakovljevic, Institute of Cellular Medicine, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, United Kingdom. Tel: +44 (0) 191 208 8257. Email address: djordje.jakovljevic@newcastle.ac.uk

Thankyou for highlighting the affiliations. A few changes need to be made which include:

1-Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne, UK
2- Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK
3- Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
4- Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

2+3 will be included on Guy A. MacGowan

4-roy and kieren

Add in chris day and djordjes new one

1: The addition of "All authors read and approved the final manuscript" at the end of the 'Authors' contributions' section is fine, the authors are happy with this addition.

2: Reference [1] should be changed to

3: Reference [13] volume is 37 and page numbers should be changed to 3092-7

4: Thankyou for highlighting the affiliations. A few changes need to be made. which include:

1- Institute of Cellular Medicine, MoveLab, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK

2-Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK

4-Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
Abstract:

Background: Bioreactance is a novel non-invasive method for cardiac output measurement that involves the analysis of blood flow-dependent changes in the phase shifts of electrical currents applied across the chest. The present study evaluated the test-retest reliability of bioreactance for assessing hemodynamic variables at rest and during exercise.

Methods: 22 healthy participants (26 (4) years) performed an incremental cycle ergometer exercise protocol relative to their individual power output at maximal O₂ consumption (Wmax) on two separate occasions (trials 1 and 2). Participants cycled for five 3 min stages at 20, 40, 60, 80 and 90% Wmax. Haemodynamic and cardiorespiratory variables were assessed at rest and continuously during the exercise protocol.

Results: Cardiac output was not significantly different between trials at rest (p = 0.948) nor at any stage of the exercise protocol (all p > 0.30). There was a strong relationship between cardiac output estimates between the trials (ICC = 0.95, p < 0.001) and oxygen consumption (ICC = 0.99, p < 0.001). Stroke volume was also not significantly different between trials at rest (p = 0.989) or during exercise (all p > 0.15), and strong relationships between trials were found (ICC = 0.83, p < 0.001).

Conclusions: The bioreactance method demonstrates good test-retest reliability for estimating cardiac output at rest and during different stages of graded exercise testing including maximal exertion.

Key words: Bioreactance, Cardiac Monitoring, Cardiac Output, Graded Exercise
Introduction

Monitoring of cardiac output (CO) has wide clinical application in anesthesiology, emergency care and cardiology. It can improve outcomes, establish diagnosis, guide therapy and help risk stratification in different clinical groups. Measurement of cardiac output is essential in critically ill, injured and unstable patients as it provides an indication of systemic oxygen delivery and global tissue perfusion. Cardiac output monitoring during surgery is associated with reduced length of hospital stay and postoperative complications. Measurement of cardiac output under pharmacological and physiological stimulations defines overall function and performance of the heart, predicts prognosis and survival in heart failure can help explain the mechanisms of exercise intolerance, and improves risk stratification.

Thermodilution and direct Fick remain the “gold standard” and reference methods for assessing CO. Whilst “gold standard” these methods have inherent limitations as they are invasive, costly, require specialist skills and associated with noteworthy risks and complications such as catheter-related infections, arrhythmias and bleeding. The risk:benefit ratio of these assessment methods has also been brought into question. These limitations preclude the use of invasive cardiac output monitoring in large number of patients limiting the application of this useful diagnostic and prognostic marker.

Over the previous decades several minimally invasive and non-invasive methods for assessing cardiac output have been developed including; trans-esophageal Doppler, transpulmonary thermodilution, pulse contour and pulse power analysis, and non-invasive techniques such as CO$_2$ and inert gas rebreathing, transthoracic Doppler, thoracic bioimpedance cardiography, and electrical velocimetry (modified bioimpedance).
Unfortunately whilst these methods are safe they are associated with certain limitations precluding their accuracy and reliability. Bioreactance, a novel method for continuous non-invasive cardiac output monitoring, has received increased attention in clinical and research practice in the recent years. The bioreactance method estimates CO by analysing the frequency of relative phase shift of electronic current across the thorax. In contrast to impedance cardiography which is based on the analysis of transthoracic voltage amplitude changes in response to high frequency current, the bioreactance analyses the frequency spectra variations of the delivered oscillating current. This approach is supposed to result in the improved precision of the bioreactance system as demonstrated by a 100 fold larger signal-to-noise ratio than that of bioimpedance and thus make it less susceptible to interference from adipose tissue, electrode placement and excessive movement.

The ability of bioreactance to monitor rapid changes in blood flow has recently been confirmed by Marik, et al. The authors compared carotid Doppler against bioreactance in patients with unstable cardiac conditions during passive leg raising. A strong correlation was reported in blood flow between the two methods in critically ill patients, with an accelerated response to these volume changes reported by bioreactance. Bioreactance cardiac output monitoring has been used in intensive care unit, during and following cardiac surgery, patients with chronic obstructive pulmonary disease and healthy individuals. Other studies demonstrated that bioreactance measurements of cardiac output at rest and during exertion can identify cardiovascular function abnormalities, indexing disease severity, help prognosis and risk stratification, and track responses to treatment in clinical practice.
When assessing cardiac output at rest or during physiological challenge, it is essential that method demonstrates acceptable level of reliability i.e. test-retest reliability which refers to the reproducibility of values of a variable when measured the same subjects twice. This is important because even small changes in cardiac output and stroke volume may have significant clinical implications when evaluating the effect of pharmacological and non-pharmacological interventions and risk stratification. Based on available literature, it appears that test-retest reliability of bioreactance, as a novel and potent method for non-invasive continuous cardiac output monitoring has not been evaluated. Based on higher signal-to-noise ratio and improved performance\textsuperscript{19,20} we hypothesize that bioreactance method demonstrates acceptable test-retest reliability for evaluating cardiac output at rest and during physiological stimulation such as graded exercise testing. Additionally, we evaluated association between cardiac output and oxygen consumption at peak exercise.

14 Methods

All experimental procedures were approved by the Faculty’s Research Ethics Committee in accordance with the Declaration of Helsinki. In all cases, after being informed of the benefits and potential risks of the investigation all participants completed a standardised health-screening questionnaire, undertook a resting electrocardiogram and gave their written informed consent.

Twenty two healthy individuals (10 males and 12 females) mean age 22 participated in the study. All participants were non-smokers and free from any cardiac and respiratory disorders. All participants attended the exercise laboratory on 2 separate days, day 1 involved an initial assessment of maximal aerobic capacity ($\dot{V}O_{2\text{max}}$) and day 2 required 2
visits consisting of an incremental exercise cycle ergometer protocol at individual pre-
determined workloads based on participants power output at $\dot{V}O_{2\text{max}}$ (Wmax). Participants
were required to abstain from eating for a minimum of 2 hours prior to the commencement of
each test and from vigorous exercise 24 hours prior to the test. Participants were also
instructed not to consume alcohol and caffeine containing foods and beverages on test days.

Participants completed a maximal progressive exercise test on an electro-magnetically braked
recumbent cycle ergometer (Corival, Lode, Groningen, Netherlands). All participants began
cycling against a resistance of 40 W, this increased continually throughout the test at a ramp
rate of 15 W min\(^{-1}\). Cessation of the assessment occurred when participants reached volitional
exhaustion or were unable to maintain a cadence of 60-70 revolutions per minute. It was
considered that a maximal effort was achieved if participants met any of two of the following
criteria: i) a change in $\dot{V}O_2 < 2$ ml kg min\(^{-1}\) across two stages of the incremental test; ii) a
respiratory exchange ratio of 1.15 or greater, or iii) ≥ 90% age predicted maximum heart rate
(220-age)\(^{28}\). Expired gases were measured via online metabolic gas exchange system (Cortex
metalayer 3B, Leipzig, Germany) and heart rate was measured via short range telemetry
(Polar RS400, Finland). Peak oxygen consumption was defined as the average oxygen uptake
during the last minute of exercise, expressed as millilitres per kilogram of body weight per
minute and litres per minute. The Wmax was defined as the power output expressed in W at
the point at which participants reached their individual $\dot{V}O_{2\text{max}}$.

Exercise protocol was performed twice on study day 2 with ≥ 3 h interval between trials 1
and 2. Participants were required to complete five 3 min stages (equating to 15 min of cycling)
at intensities relative to 20, 40, 60, 80 and 90% Wmax. Cardiac and hemodynamic responses
including cardiac output, cardiac index, stroke volume and stroke volume index, and heart
rate were recorded at rest and throughout the incremental exercise protocol using a non-
invasive bioreactance system (NICOM®, Cheetah Medical, Delaware, USA). Simultaneously, 
respiratory and gas exchange measurements were recorded (Cortex metalyser 3B, Leipzig, 
Germany).

The bioreactance system comprises of a radio frequency generator that creates a high 
frequency current that is introduced across the thoracic cavity. The NICOM® has been 
described previously19,20,25. It analyses the relative phase shift of electronic current across the 
thorax. In brief the four dual surface electrodes are used to establish electrical contact with 
the body. The skin was prepared by shaving where required and using adhesive paper to 
ensure an optimal signal from the electrodes. Two electrodes were placed over the trapezius 
muscle on either side of the upper torso and two on the lower posterior torso lateral to the 
margin of the latissimus dorsi musculature. The right and left sensors of the devise generate 
independent signals which are subsequently integrated to generate the final signal analysed. 
The blood that is present in the thoracic cavity absorbs electrons, which results in a delay in 
the signal, which is proportional to the volume of blood flow. This is called a phase shift and 
is recorded and the figure is translated to the flow of the blood. The signal that is detected by 
the electrodes is then processed separately and averaged after digital processing at 30 or 60 s 
intervals. The signal processing unit of the NICOM® determines the relative phase shift (Δφ) 
between the input signals relative to the output signal. The Δφ is in response to any changes 
in blood flow that pass through the aorta. The CO is then derived by CO = (C x VET x Δφ 
dtmax) x HR, where C is the constant of proportionality and VET is ventricular ejection 
fraction time19. The value of C has been previously validated to account for patient age, 
gender, height and weight22. CO can then be calculated from stroke volume and HR.
Statistical methods

Statistical analyses were performed using PASW statistical analysis software (Version 19, IBM, USA). Data are presented as mean (standard deviation). The alpha level of 0.05 was set prior to data analysis and normality of distribution was assessed using a Kolmogorov-Smirnov test. Relative reliability was determined using intra-class correlation coefficients (ICC), calculated using the two-way random method previously described by Weir\textsuperscript{29}. Absolute reliability was determined using standard error of measurement (SEM) with 95% confidence intervals (95%CI), which were calculated independently of intra-class correlation coefficients. Systemic bias in the repeatability between trials was assessed using paired sample t-tests. The relationship between cardiac output and oxygen consumption was assessed with Pearson’s coefficient of correlation. Data analyses were performed on both combined resting and exercise data and data from each individual stage of the incremental exercise protocol for CO, cardiac index (CI), stoke volume (SV), stroke volume index (SVI), heart rate (HR) minute ventilation (VE) and oxygen consumption ($\dot{V}O_2$).

Results

Physical characteristics of study participants are: age 26.3 (4.2) years, height 171.5 (8) cm, body mass 67.4 (7.9) kg, and peak oxygen consumption 41.5 (8.7) ml kg min\textsuperscript{-1}. Data pertaining to the systemic bias between trials for all assessed cardiac and respiratory variables are presented in Table 1. There was a non-significant (< 5%) difference between trials 1 and 2 for all variables ($p > 0.05$).

Table 1 about here
Reliability statistics for cardiac and respiratory responses to the incremental exercise protocol are presented in Tables 2 and 3. These data demonstrate strong relative (Table 2) and test-retest absolute (Table 3) reliability.

\textit{Table 2 about here}

Cardiac output was similar between the trials 1 and 2 at rest (0.7 (10.3) %) and all stages of the incremental exercise protocol (Figure 1). At low exercise intensity i.e. 20-40% of Wmax the differences in cardiac output between trials 1 and 2 were 4 and 1%, respectively. At moderate (i.e. 60% of Wmax) and high (80 and 90% of Wmax) exercise intensity the difference was only between 1 and 2% (Figure 1).

\textit{Table 3 about here}

Non-significant differences between the trial 1 and 2 were reported for stroke volume at all stages of the protocol, with mean difference ranging from 1% (at 80% of Wmax) to 7% (at 20% of Wmax, Figure 2). When resting and exercise data points are considered together (n=132), the mean difference between trial 1 and 2 was only 2%.

\textit{Figure 1 about here}

Participants mean cardiac index and stroke volume index were not significantly different between the trials when data analyses included combined resting and exercise data (Table 1). Furthermore, neither mean cardiac index nor stroke volume index was significantly different between trials at rest or at any exercise stage.
As detailed in Table 1 heart rate, peak oxygen consumption, and mean ventilation were similar between trials. Relative and absolute reliability statistics presented in Tables 2 and 3 demonstrate good reliability. In addition, no significant differences between the trials were found in heart rate, peak oxygen consumption, and mean ventilation at rest or at any of the exercise intensities ($p > 0.05$).

Data demonstrate a strong relationship between cardiac output and oxygen consumption at peak exercise for both trials (Trial 1; $r = 0.64$, $p = 0.001$, Trial 2; $r = 0.66$, $p < 0.001$).

**Discussion**

The primary finding of this study is that bioreactance demonstrates acceptable test-retest reliability for estimating cardiac output and stroke volume at rest and during physiological stress induced by exercise testing. Additionally, the exercise protocol employed in the present study elicited similar cardiorespiratory responses between trials and a strong relationship was identified between cardiac output and peak oxygen consumption for both trials. This illustrates the ability of the exercise protocol to elicit reliable hemodynamic and cardiorespiratory responses on separate occasions in the absence of changes in health and clinical status of an individual.

The assessment of cardiac output in a reliable manner is an essential tool to accurately assess any improvements or decrements in cardiac function of numerous patient groups. As previously stated this is of particular importance in cardiac patients as small changes in
cardiopulmonary data due to disease or intervention may have significant clinical implications. It may therefore be suggested that inaccurate and unreliable measures may contribute to misinterpretation of data and potentially misdiagnosis. The excellent reliability of bioreactance in measuring haemodynamics (at rest and continuously during exercise) reported in the present study illustrates its potential clinical application. Furthermore, its ability to assess cardiac output noninvasively, inexpensively and without specialist training of the assessor permits its application in an increased number of patient groups when compared to more invasive and “gold standard” catheter based measurement techniques.

The CO values reported in the present study are consistent with recent research employing bioreactance in a comparable population and at similar exercise intensities. The authors Jakovljevic, et al. reported resting CO values of 6.5 L min⁻¹ which are similar to those reported in the present study. Similar values were also reported at comparable submaximal and near maximal exercise intensities. Furthermore the CO data previously reported was consistently correlated with CO estimates derived from measured oxygen consumption. We have also demonstrated a strong relationship between cardiac output and oxygen consumption at peak exercise in the present study. Elliott, et al. also reported similar CO as assessed via bioreactance at similar exercise intensities as the present study and previous study. In addition resting and near maximal cardiac index reported in the present study is similar to that previously reported. The data presented in this article further substantiates the previous work and demonstrates that bioreactance is accurate and reliable for assessing haemodynamic variables at various exercise intensities. Furthermore, cardiac output data from the present study that are associated particularly with stages of low to moderate intensities are consistent with those identified in different stages of heart failure.

Overall, data presented in the present study indicate that bioreactance can provide reliable
measures of cardiac output independent of any other physiological measures (e.g. oxygen consumption) and potential elevated electrical noise, body motion, perspiration and body temperature associated with graded exercise.

The present study is not without limitations. Firstly, the study participants were young, healthy adults whereas older people and those with chronic conditions were not included. It may be speculated therefore that the present findings cannot be generalized to a wider, clinical applications. However, the study protocol allowed analysis of bioreactance cardiac output test-retest reliability not only at peak exercise but also at low to moderate levels of exercise intensities that are often observed in individuals with chronic conditions and in older people. Secondly, no gold standard for cardiac output measurement (i.e. thermodilution or direct Fick) was included. The additional risks posed to the study participants with these procedures precluded them from being undertaken.

**Conclusions**

In conclusion, bioreactance method demonstrates good test-retest reliability for estimating cardiac output and stroke volume at rest and during different stages of graded exercise testing including maximal exertion. Future large studies are warranted to assess the reliability of bioreactance at both rest and exercise in different clinical groups where monitoring of cardiac output has been shown to improve risk stratification and clinical outcomes.
**Author contributions:**
1. Study conceived and designed by DGJ, TWJ and DH.
2. Data collection performed by DGJ, TWJ, DH and SC.
3. Data extraction and analyses performed by TWJ.
4. Interpretation of data and preparation of manuscript performed by DGJ, TWJ, DH, SC, GAM and MIT.

**Acknowledgements:**

**Conflict of Interest disclosures:**
This study is *not* industry sponsored; TWJ, DH, MIT, SC, GAM and DGJ report no conflict of interests.

**Funding:**
This work was supported by the UK National Institute for Health Research Biomedical Research Centre for Ageing and Age-related Diseases award to Newcastle upon Tyne Hospitals NHS Foundation Trust. MIT is supported by the UK National Institute for Health Research Senior Research Fellowship. DGJ is supported by the Research Councils UK Centre for Ageing and Vitality. The funding sources did not have a direct role in the design, collection, analysis or interpretation of data, nor in the manuscript preparation, which is solely the remit of the author(s).

**Guarantor statement:**
Thomas W. Jones and Djordje G. Jakovljevic take responsibility for the content of the manuscript, including the data and analysis.

**Notation of prior abstract publication/presentation:**
N/A
References


10 Lang CC, Karlin P, Haythe J, Lim TK, Mancini DM. Peak cardiac power output, measured noninvasively, is a powerful predictor of outcome in chronic heart failure. Circ Heart Fail 2009; 2: 33-8


12 Gawlinski A. Measuring cardiac output: intermittent bolus thermodilution method. Critical Care Nurse 2004; 24: 74-8


16 Mathews L, Singh KR. Cardiac output monitoring. Ann Card Anaesth 2008; 11: 56-68


Tables

Table 1. The mean values and standard deviations for cardiac and respiratory variables obtained at rest and during the incremental exercise protocol.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Trial 1</th>
<th>Trial 2</th>
<th>t-test (p-value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac output (L min⁻¹)</td>
<td>13.7 (4.4)</td>
<td>13.4 (4.1)</td>
<td>0.518</td>
</tr>
<tr>
<td>Heart rate (beats min⁻¹)</td>
<td>123.7 (37.8)</td>
<td>124.3 (36.7)</td>
<td>0.905</td>
</tr>
<tr>
<td>Stroke volume (ml beat⁻¹)</td>
<td>112.9 (22.5)</td>
<td>109.5 (18.7)</td>
<td>0.179</td>
</tr>
<tr>
<td>Minute ventilation (L min⁻¹)</td>
<td>46.2 (30.0)</td>
<td>47.6 (30.3)</td>
<td>0.732</td>
</tr>
<tr>
<td>Oxygen consumption (L min⁻¹)</td>
<td>1.6 (0.9)</td>
<td>1.6 (0.9)</td>
<td>0.882</td>
</tr>
</tbody>
</table>

Note: p value determined from test-retest data using paired sample t-test for measurement outcomes. Data analyses performed on resting and exercise data combined (n = 22, data points =132).
Table 2. Relative reliability statistics for cardiac and respiratory variables at rest and during the incremental exercise protocol.

<table>
<thead>
<tr>
<th>Variable</th>
<th>ICC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac output (L min(^{-1}))</td>
<td>0.95*</td>
</tr>
<tr>
<td>Heart rate (beats min(^{-1}))</td>
<td>0.99*</td>
</tr>
<tr>
<td>Stroke volume (ml beat(^{-1}))</td>
<td>0.88*</td>
</tr>
<tr>
<td>Minute ventilation (L min(^{-1}))</td>
<td>0.99*</td>
</tr>
<tr>
<td>Oxygen consumption (L min(^{-1}))</td>
<td>0.99*</td>
</tr>
</tbody>
</table>

*Significant correlation between trials 1 and 2 (\(p < 0.001\)). Data analyses performed on resting and exercise data combined (n = 22, data points = 132).
Table 3. Absolute reliability statistics for cardiac and respiratory variables at rest and during the incremental exercise protocol.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Change in mean (%</th>
<th>95%CI</th>
<th>Sx</th>
<th>SRD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac output (L min(^{-1}))</td>
<td>11.1 ±0.7</td>
<td>±3.0</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>Heart rate (beats min(^{-1}))</td>
<td>6.7 ±6.4</td>
<td>±26.3</td>
<td>10.3</td>
<td></td>
</tr>
<tr>
<td>Stroke volume (ml beat(^{-1}))</td>
<td>9.8 ±3.5</td>
<td>±14.6</td>
<td>5.7</td>
<td></td>
</tr>
<tr>
<td>Minute ventilation (L min(^{-1}))</td>
<td>12.0 ±5.4</td>
<td>±21.3</td>
<td>8.4</td>
<td></td>
</tr>
<tr>
<td>Oxygen consumption (L min(^{-1}))</td>
<td>12.1 ±0.2</td>
<td>±0.7</td>
<td>0.3</td>
<td></td>
</tr>
</tbody>
</table>

Note: Sx = standard error of the mean, SD = standard deviation, SRD = smallest real difference. Data analyses performed on resting and exercise data combined (n = 22, data points = 132).
**Figure legends**

**Figure 1.** Mean cardiac output at rest and at individual stages of the incremental exercise protocol on trials 1 and 2. Wmax = power output in Watts (W) at \( \dot{V}O_{2\text{max}} \) (n = 22).

**Figure 2.** Mean stroke volume at rest and at individual stages of the incremental exercise protocol on trials 1 and 2. Wmax = power output in Watts (W) at \( \dot{V}O_{2\text{max}} \) (n = 22).